DermaPrecise

DermaPrecise Injection System Shown to Produce Consistently High Cell Count and Viability for Cell Therapy Injections.

Independent Testing Performed by Innovacell Demonstrates the DermaPrecise™ Control Leads to Unparalleled Post-Injection Cell Survival and Viability Consistency.

https://www.accesswire.com/viewarticle.aspx?id=710326

Given the system's control over injection depth, the injection can be optimized to deliver cells where they need to be to have an optimal clinical effect. DermaPrecise™ thus assists product developers and clinicians in controlling for delivery variability as an influence on clinical outcome variability.

"The test results show that DermaPrecise™ has the potential to greatly improve consistent post-injection cell viability in the delivery of cells injected into dermal or subcutaneous tissue. Improved, controllable, consistent, validated cell-delivery tools are required to optimize cell therapy outcomes for patients and the companies developing these valuable therapies," stated Kevin McElwee, RepliCel's Chief Science Officer.

Laboratory Test Results Confirm Value of DermaPrecise (TM) Injection Consistency in Clinical Simulation Testing.

Independent dermatology research experts at Monasterium Laboratory GmbH tested, analyzed and validated various injection parameters using donated human tissue

https://t.co/rFR6p1cd88

RepliCel’s Manufacturing Inspected by Japan’s PMDA After over a year of pandemic-related delays, representatives of Japan's PMDA, attended at the Company's contract manufacturing facility, Innovacell, to review the manufacturing of RepliCel's NBDS cell therapy products VANCOUVER, BC / ACCESSWIRE / July 28, 2022 / RepliCel Life Sciences Inc. (OTCPINK...